|
(V1080) |
Scalable Ultra-Purification of Adeno-Associated Viral Vectors - A Novel Standard to Boost Transduction Efficacy and Potency for Cardiac Gene Therapy Development |
| |
|
A. Jungmann, S. Simon, P. Schlegel, E. Meinhardt, C. Steeg, J. Kroemer, T. Ruppert, C. Richter, M. Neßling, P. Raake, H. A. Katus, N. Frey, P. Most, M. Busch (Heidelberg, Augsburg) |
|
|
Diskussion |
|
(V1081) |
Specific targeting of cardiac fibroblasts by capsid engineered and in vivo selected adeno-associated viral vectors |
| |
|
S. Groß, L. Rode, S. Biß, H. Büning, C. Bär, T. Thum (Hannover) |
|
|
Diskussion |
|
(V1082) |
CRISPR mediated activation of DLK1 ameliorates contractile dysfunction in Engineered Human Myocardium |
| |
|
N. Bader, A. Rika, B. Berecic, E. Schoger, E. Buchholz, K. Toischer, L. Zelarayán, S. von Haehling, W.-H. Zimmermann, M. Tiburcy (Göttingen) |
|
|
Diskussion |
|
(V1083) |
Cytokine adsorber treatment improves contractility of the left ventricular after circulatory arrest |
| |
|
L. Saemann, P. Kraft, K. Wächter, F. Hoorn, S. Pohl, G. Veres, S. Korkmaz-Icöz, F. Wenzel, M. Karck, A. Simm, G. Szabó (Halle (Saale), Heidelberg, Villingen-Schwenningen) |
|
|
Diskussion |
|
(V1084) |
In Vivo Retargeting of AAV9 to Cardiac and Skeletal Muscle Pericytes |
| |
|
T. Bozoglu, T. Ziegler, S. Hanusch, A. Hönig, I. M. Luksch, A. Bähr, C. Kupatt (München) |
|
|
Diskussion |
